GoodRx (GDRX) Stock: $20 Price Target And Hold Rating

By Amit Chowdhry ● Mar 3, 2022
  • The shares of GoodRx Holdings Inc (NASDAQ: GDRX) have received a $20 price target. These are the details.

The shares of GoodRx Holdings Inc (NASDAQ: GDRX) have received a $20 price target. And  Deutsche Bank analyst George Hill is maintaining a “Hold” rating on the shares.

Hill adjusted the rating following the company’s fourth-quarter results. The quarterly EPS was $0.09, which was below the consensus estimate of $0.10.

And revenue was $213.3 million, compared to the consensus estimate of $217.53 million. The Prescription Transactions revenue increased 21% year-over-year to $158.8 million, driven by a 14% increase in monthly active consumers (MAC) and an ongoing increase in revenue per MAC. And subscription revenue was $17.4 million, up 79% year-over-year – driven by a 51% increase in the number of subscription plans and a favorable change in the subscription plan mix.

The company’s Board of Directors also authorized the repurchase of up to $250 million of its Class A common stock.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.